Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy.
Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy.
复制标题
甲羟孕酮对抑郁和非抑郁围绝经期和绝经后妇女停止经皮雌二醇治疗后抑郁症状的影响。
DOI：
10.1097/gme.0b013e3182333847
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Joffe,Hadine
中科院分区：
文献类型：
--
作者：
Rogines-Velo,MariaPia;Heberle,AmyE;Joffe,Hadine
ObjectiveConcern about adverse effects of progestins on mood has influenced the use of medroxyprogesterone (MPA) and other progestins. In this brief report, we examined whether the administration of MPA leads to depressive symptoms in two groups of perimenopausal and postmenopausal women randomly assigned to treatment with estrogen: one currently experiencing clinical depression and another without depression.MethodsOpen-label MPA 10 mg/day was administered for 14 days for endometrial protection after completion of double-blinded treatment with 17β-estradiol 0.1 mg/day for 8 to 12 weeks in 40-to 60-year-old perimenopausal and postmenopausal women enrolled in two separate randomized placebo-controlled trials for treatment of cognitive problems (“nondepressed group”) or clinical depression (“depressed group”). Nonparametric tests were used to compare changes in depressive symptoms on the Beck Depression Inventory (BDI) within each group and between groups during MPA therapy.ResultsOf the 24 nondepressed (median BDI at baseline, 5.5; interquartile range [IQR], 2.5-8.5) and 14 depressed (median BDI at baseline, 17; IQR, 15-21) women treated with MPA, the BDI scores did not change during MPA treatment in either group (median change, 0; IQR,− 2 to 0.5 and median, 0; IQR,− 0.5 to 1.5, P= 0.28 and P= 0.50, respectively). Changes in BDI scores during treatment with MPA did not differ between groups (P= 0.25).ConclusionsAmong women receiving MPA for 2 weeks after discontinuation of estradiol, depressive symptoms did not emerge on MPA. These findings were consistent for both depressed and nondepressed women, suggesting that, even among women who are currently experiencing depression, brief treatment with MPA is unlikely to disrupt mood.
